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Abstract 
This project aims to improve the SIV/rhesus macaques animal model for AIDS. 
TRIM5α is an antiviral molecule expressed in mammals including rhesus macaques. 
The antiviral specificity determinant of TRIM5α is within the B30.2 domain, encoded 
within the last exon of the TRIM5 gene. This work assessed whether B30.2 
polymorphism is responsible for differences in disease progression following retroviral 
challenge.  Exon 8 from TRIM5 was amplified by PCR and sequenced to identify the 
different alleles of the B30.2 domain, termed Macaca mulatta (Mamu) alleles. These 
were appended to the remainder of the TRIM5 molecule, creating TRIM5α molecules 
with varying B30.2 domains. These were expressed in a highly permissive cell line, 
CRFK. A variety of green fluorescent protein (GFP) expressing retroviruses were 
generated within HEK 293T cells and used to infect CRFK that express different forms 
of TRIM5α. Retroviral infection was assessed using a FACS machine, which counts 
GFP positive cells. This is a method of analysing differences in retroviral restriction 
potentials due to expression of B30.2 polymorphs. Furthermore, this project examined 
the dominant negative properties of the identified Mamu alleles against a strong 
restriction of HIV-1, Mamu1. Cells were protected from infection with FIV, HIV-1, 
HIV-2 and EIAV by some of the Mamu alleles tested, except Mamu7. In contrast, SIV, 
MLV-B and MLV-N were not restricted by any of the Mamu alleles tested in this study. 
Interestingly Mamu4 and Mamu5 protected cells from HIV-1, FIV and EIAV infection 
but not from HIV-2 infection. These alleles therefore appear to encode functional 
restriction factors with different antiretroviral specificities. Mamu7, a truncated allele 
showed the least restricting properties of all tested alleles. However, co-expression of 
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Mamu7 with the wildtype TRIM5α allele was found to slightly abrogate restriction in a 
dominant negative manner following challenge with HIV-1 and HIV-2. In addition, 
Mamu4 and 5 exerted a mild dominant negative effect following HIV-2 infection, 
consistent with their inability to restrict HIV-2 when expressed alone. 
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Introduction 
The identification of an animal model for AIDS vaccine studies continues to present a 
significant challenge. One important facet of an ideal animal model is that it has to show 
a reproducible disease progression in an infected animal. Specifically, it is useful to 
know if the reason animals do not become sick following retroviral challenge is due to 
their genotype or due to vaccination. It has become apparent that some rhesus macaques 
are resistant to disease after challenge with SIVmac and do not become ill. Clearly such 
animals are not useful AIDS animal models. There is a need to identify the factors that 
contribute to this resistance before an animal is enrolled for vaccine trials.   
 
Recent studies in infectious disease research have revealed the existence of antiviral 
cellular factors that have evolved within mammals due to selection pressure from 
pathogenic viruses. These are termed restriction factors and they present an important 
and very challenging area of this field. In function, they contribute to an innate immune 
barrier against a range of viruses (1, 2). Amongst the well known restriction factors is 
the tripartite motif protein (TRIM) family, some of which have been found to have 
antiviral properties. One member of the family (TRIM5α) is antagonistic to the 
replication of both lentiviruses and gammaretroviruses in a species-specific manner. For 
example, infection with the human immunodeficiency virus (HIV-1) is potently 
restricted by rhesus macaques TRIM5α, but conversely, human TRIM5α does not 
restrict HIV-1 infection (3, 4). TRIM5α was discovered in 2004 following the screening 
of a cDNA library from rhesus macaques to identify cDNAs with antiviral activity 
against HIV-1 (2). TRIM5α act in the cytoplasm of the host cell (4, 5) and the 
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expression of this protein is induced by interferon via the interferon regulatory factor 3 
(IRF3) binding the TRIM5 promoter. IRF3 is a transcription factor that mediates a 
specific gene expression program involved in the innate antiviral response (6). 
 
The TRIM5 gene is alternatively spliced, leading to a number of isoforms of the protein 
product (figure 1) each of which is shorter from the C-terminus. TRIM5γ and TRIM5δ, 
both lack the B30.2 domain, a ret finger-like protein (RFP) domain consisting of the 
combination of a PRY and SPRY (PRY-SPRY) domain on their carboxy-terminal (5, 7, 
8). TRIM5α is the longest isoform (~493 amino acid residues with a molecular mass of 
54 to 56 kDa per monomer in rhesus macaques) (5, 9, 10) and the only isoform that 
encodes a B30.2 domain. The B30.2 domain is known to interact directly with the 
incoming viral capsid. Additionally, it is the only isoform with antiviral activity 
illustrating the importance of the B30.2 domain in this regard (1, 4, 7). Rhesus TRIM5α 
specifically binds the HIV-1 capsid in an interaction that is dependent on the B30.2 
domain (9). The shorter isoforms, Rhesus TRIM5γ and TRIM5δ exert a dominant 
negative effect that represses restriction, by the wildtype TRIM5α, rescuing restricted 
infectivity following their over-expression (1, 2, 11). This is thought to occur through 
the titration of viral binding B30.2 domain due to heteromultimers formed by TRIM5γ 
and TRIM5δ via the coiled coil (2). The B30.2 domain contains three or four variable 
regions (V1, V2, V3 and V4) which vary between different TRIM5 B30.2 domains and 
are thought to have been subjected to very strong positive selection pressure from 
retroviruses. In this regard, it is vital to mention that the rhesus macaques TRIM5 gene 
has numerous polymorphisms that are found in the variable loops, (2). Importantly, 
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TRIM5α variable regions also influence antiviral specificity. Studies on the binding 
specificities of TRIM21 have revealed two substrate binding surfaces one of which is 
found in the PRY (V1) and another in the SPRY (V2-V3) loops and this is also thought 
to be the case for TRIM5α (2). This is also supported by reports that the SPRY domain 
recognises an intricate structure that is only found in the core of susceptible viruses 
(12). 
 
B30.2 is found on a single exon (8) of the TRIM5 gene (figure 1A and 1B) (8, 13, 14). 
Its contribution to retroviral restriction and disease progression following retroviral 
infections constitute the basis of this investigation. 
 
 
Fig 1A and B: The domain structure of TRIM5. An illustration of TRIM5α showing 
the domain structure of TRIM5α proteins (A) and the eight exons in different TRIM5 
isoforms, (B) (14) of interest in this work is TRIM5α exon 8, the B30.2 domain. 
 
  
 
B  
RING B30.2 (PRY-SPRY) A  B-box Coiled-coil 
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TRIMs are also called RBCC proteins, constituting a RING (really interesting new 
gene), domain that encodes two atypical zinc fingers and is involved in specific protein-
protein interactions. Numerous RING domains comprise E3 ubiquitin ligase activity; 
indeed a RING dependent autoubiquitinylation can be mediated by TRIM5 in vitro (2, 
15). Another report states that a disruption of this domain results in the mislocalisation 
of TRIM5αrh and a reduction in the cytosolic levels of the protein in comparison to the 
wildtype protein. Furthermore it has been shown that RING mutants retain their 
retroviral inhibition abilities (5). TRIMs also consist of one of either 2 types of B boxes, 
B-box1 or B-box2; these domains have a zinc-binding motif and are assumed to be 
involved in protein-protein interactions. TRIM5 has a B-box 2 (2, 9). B-box 2 also 
seems to be necessary for efficient retroviral inhibition. Additionally, B-box 2 mutants 
have been reported to associate with the wildtype TRIM5α, interfering with its 
antiretroviral activity in a dominant negative way (5). TRIMs also encode a coiled coil 
domain, involved in the homo- and hetero-multimerisation of the whole protein and 
mediates trimerisation; (2, 9) some TRIMs also have a B30.2 which also functions in 
protein-to-protein interactions (7, 16-18). A defining characteristic for TRIM5α is that it 
is the longest and the only TRIM5 with a B30.2 domain; additionally it is the only one 
with an antiretroviral activity (1, 7, 16, 17). This has highlighted that the B30.2 domain 
is the restriction specificity determinant, essential for viral restriction (16, 17, 19). 
Crucially, this domain is recruited to incoming viral cores and is necessary for capsid 
recognition and binding (2, 17). TRIM5 molecules lacking the PRY-SPRY domain do 
not have antiretroviral activity (17). Furthermore, there is evidence that the ability of 
TRIM5α to bind a viral capsid is not adequate for complete viral restriction (5). 
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TRIM5α mutants lacking the RING and/or B-box 2 domains have been shown to bind 
and form complexes with HIV-1 capsid-nucleocapsid but were partially or completely 
unable to effect viral restriction, suggesting that the amino-terminal elements of the 
restriction factor function as effector domains (5, 9).  
 
Both human and monkey TRIM5α derivatives have been shown to block the entry of a 
group of retroviruses, (16, 17, 20, 21) with HIV-1 strongly inhibited by rhesus TRIM5α 
(17, 21). In humans, HIV-1 has evolved and adapted to evade human TRIM5α activity 
(8, 22). TRIM5α is a dominant antiviral factor; illustrated by the fact that the block to 
infection could be saturated or abrogated by elevated concentrations of retroviral cores 
(4). Importantly, retroviral capsid structures are conserved with capsid hexamers found 
in both lentiviruses and gamma retroviruses and therefore TRIMs are presumed to 
recognise a conserved capsid surface (2, 12). However, a single point mutation can 
result in a virus that escapes restriction and thus the effectiveness of TRIM5 in viral 
restriction continues to puzzle researchers in this field; this is in light of the fact that 
minor changes in the viral capsid can rescue infectivity and also that retroviral capsid 
sequences are rather plastic (2). Summarily, susceptibility to TRIM5α restriction is also 
largely determined by viral capsid sequences and the determinants of susceptibility map 
to the capsid protein (9). 
 
Upon cell entry retroviruses sequentially undergo a series of steps that serve to establish 
productive infection; these viral steps include viral core uncoating, reverse transcription, 
trafficking to and nuclear entry, and viral DNA integration into the host genome (4). 
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TRIMs are constitutively expressed in many tissues (21, 22) and are induced by 
interferons, highlighting their innate immune role (16). TRIM5α forms a trimer that 
interacts with the hexameric retroviral capsids; this molecule is ubiquitinylated within 
cells and is rapidly turned over by the proteasome in a RING domain dependent 
manner, this implies that the process might be mediated by autoubiquitinylation (2, 10). 
Although the complete mechanism of action of TRIM5α has not yet been fully 
characterized, it is thought that upon viral binding and fusion with the target cell, 
TRIM5α interferes with the early uncoating steps required to liberate viral nucleic acids 
into the cytoplasm and that rapid turnover of both TRIM5α and TRIM5α-viral 
complexes results in early infection blockade, prior to viral reverse transcription (2, 5, 
23). Forshey et al. suggest that the process of capsid uncoating is tightly regulated 
therefore uncoating that is too rapid or too slow might in fact compromises infectivity 
of a virus (24). Suprisingly, proteasome inhibition has been found to be unable to rescue 
infectivity and has no effect on the levels of TRIM5α; (15, 25, 26) also, proteasome 
independent degradation of capsids by TRIM5α has been reported (15, 25) suggesting 
that viral degradation via proteasomes is not the key element in TRIM5α restriction. 
Additionally, other studies report unaltered levels of total cytoplasmic concentrations of 
viral capsid following the introduction of TRIM5α into cells, suggesting that the process 
does not promote capsid degradation (9). It remains unclear how TRIM5α induces viral 
restriction but it assumed that through coating the viral core with multivalent complexes 
the molecule induces debilitating disruptions to vital viral processes such as the 
rearrangement/uncoating and/or trafficking essential for migration to the nucleus for 
integration (2). Rapid uncoating of viral cores might also be involved and this has been 
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observed in the case of HIV-1, (24) a virus that is restricted by TRIM5αrh. In summary, 
it is supposed that TRIM5α restriction involves the prevention of capsid uncoating, 
accelerated uncoating, or the destruction of the viral capsid (9). These activities may not 
be mutually exclusive. 
High-affinity binding of the viral capsid is mediated by the B30.2 domain via a 
canonical binding interface of six antibody-like Variable Light chains (VLs) (27). An 
observation that very little viral DNA is synthesised in a majority of TRIM5α-restricted 
virions signifies that viral blockade occurs during the early stages of cell infection. This 
also implies that interaction between restriction factors and the incoming virion occur 
early after cell entry (28-30). The fate of a restricted virion is possibly dependent on 
factors such as the type of virus, particular TRIM5, viral dosage and the concentration 
of TRIM5α expression together with other cellular constituents. Table 1 lists some of 
the possible fates of restricted viruses.  
 
 
Table 1: The three likely fates for a restricted virion 
 
A restricted virion may: 
1. Be degraded by the proteasome 
2. Inappropriately uncoat 
3. Remain intact and make DNA but not have access to the nucleus 
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In summary, The B30.2 domain is essential for retroviral capsid binding and restriction 
(12) which protects against infection and subsequent disease progression following viral 
challenge. 
 
Brief look into dominant negative effects 
The term dominant-negative describes a gene product or protein that exhibits adverse 
effects on the normal gene product, in this case wild type TRIM5α within the same cell. 
Dominant negative processes normally occur if the mutant product retains the ability to 
interact with the same substances as the wildtype protein. The mutant product exerts a 
negative effect, preventing and exerting a negative impact on the normal functions of 
the wild type protein product. The process of dominant negative can be illustrated in 
proteins such as TRIM5α that multimerise where one part of the protein complex is 
mutant in some functional aspects of the trimer, (such as the lack of a B30.2 domain 
resulting in lack of antiviral properties) but can still form a multimer it can have a 
dominant effect on the wildtype parts of the complex and a negative effect if the 
mutation prevents the complex from fulfilling its regular functions, retroviral restriction 
(31). Consequently, the gene encoding the mutant monomer component of the trimer is 
called a dominant negative protein. 
 
TRIM5γ and TRIM5δ are the shorter isoforms of TRIM5 encoding a C-terminal that 
differs the from wildtype TRIM5α. When expressed simultaneously with a wildtype 
TRIM5α the two isoforms exert a dominant negative effect that represses HIV-1 and 
MLV-N restriction, respectively increasing permissivity of cells to viral infection and 
rescuing restricted infectivity (1, 2, 11). Additionally, a functionally defective TRIM5α 
Charlotte Maplanka 
Project Report 
 14 
mutant with the RING and B-box deleted has been found to hetrotrimerise with the wild 
type molecule exerting a dominant negative activity on retrovirus restriction (5, 10) 
 
 
The AIDS model 
Rhesus macaques TRIM5α (TRIM5αrh) restricts HIV in a species-specific manner with 
the B30.2 domain mainly responsible for the observed anti-HIV-1 potency (21, 32, 33). 
Consequently, this system cannot be used as a model for AIDS in vaccine studies. The 
best animal model therefore involves infecting rhesus macaques with a SIVmac 
derivative, a virus that is closely related to HIV-1 and has similar pathogenesis in 
macaques to HIV-1 in humans. SIVmac is known to be weakly restricted by TRIM5αrh 
(5). SIVmac infection in rhesus macaques also has similar characteristics to HIV-1 
infections in humans including progression to AIDS (30). However, it has also been 
found that individual rhesus macaques are not equally permissive to SIVmac infection 
and that not all animals develop disease after viral challenge (3, 30). This demonstrates 
differing susceptibility within a species (3) and raise the question as to whether TRIM5 
polymorphism may be responsible for these observations.  
 
Very relevant to the proposed aims of this work are the recent findings by Newman et 
al. that identified six different  Macaca mulatta alleles, designated Mamu1-6 that 
highlight polymorphism within the B30.2 domain in two divergent lineages of Old 
World monkeys (3). In this regard, it is interesting to investigate whether more Mamu 
alleles are in existence and can be identified. Additionally, polymorphic B30.2 domains 
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may cause particular TRIM5 molecules to restrict SIVmac more strongly or weakly. 
Polymorphism in both the length and encoded amino acids within the B30.2 domain 
have been highlighted and seen in all three variable regions of the B30.2 domain (1, 13, 
33). Other studies have highlighted that amino acid positions, specifically the presence 
of certain amino acids at particular sites (in particular, the ones lining the binding 
surface) of the B30.2 domain is central to viral restriction (8, 13, 34). These amino acids 
have also been shown to be highly variable which implies that the particular domains 
constitute the protein-interacting modules (34). 
 
Taken together, the above findings highlight that inter-species variation within the 
B30.2 domain affects retroviral restriction specificity within primates. Therefore, at 
present, it appears that the remaining unanswered question is whether intra-species 
TRIM5α polymorphism is indeed partially responsible for the observed differences in 
permissivity and dissimilar disease progression following retroviral challenges in 
animals enrolled in vaccine trials, which is the basis of this study. 
 
 
Background knowledge to this work 
Unpublished findings by S. Wilson from Greg Towers’ Lab have identified 2 further 
alleles, designated Mamu-7 and 8 (and another allele presently called FDFS) in addition 
to Mamu1, 3, 4 and 5, previously described by Newman et al (3). These were identified 
following the sequencing of the B30.2 domain from at least 60 Chinese and Indian 
rhesus macaques, enrolled in vaccination studies.  Mamu7 encodes a truncated B30.2 
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domain that has a different B30.2 domain with 8 non-synonymous single nucleotide 
polymorphisms in addition to an insertion/deletion; Mamu8 is a full B30.2 domain. It 
should be noted that Mamu2 and Mamu6 were not identified in the study by S. Wilson. 
Alleles Mamu1, 3, 4 and 5 were identified in both Indian and Chinese rhesus macaques 
while Mamu7 was only found in Indian macaques (Table 2) the allelic frequency for 
Mamu8 and FDFS is not shown in this table. It is not clear whether Mamu8 is a true 
polymorphism or a mutation because it was only identified in one individual (excluded 
from Table 2) 
 
 
 
Table 2: Mamu allelic frequency in rhesus macaques used in this study (reproduced 
with permission from S. Wilson)  
 
Macaca 
mulatta 
origin 
Allelic frequency 
 Mamu1 Mamu3 Mamu4 Mamu5 Mamu7 
 
Indian 
 
 
12/62 
(19.35%) 
 
 
19/62 
(30.65%) 
 
7/62 
(11.29%) 
 
8/62 
(12.9%) 
 
16/62 
(25.81%) 
Chinese 
 
4/76 
(5.26%) 
 
37/76 
(48.68%) 
25/76 
(32.89%) 
10/76 
(13.16%) 
0/76 
(0%) 
 
 
All of the identified Mamu alleles were also found to have unique B30.2 domain 
sequences, (Fig 2) the discovery of these variations within the sequences also indicated 
possibilities of differences in retroviral restriction properties among the alleles; the 
FDFS B30.2 domain sequence is not shown. The identified B30.2 domains were 
expressed in CRFK and FRHK cells (see material and methods section) and their 
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restriction properties tested against a range of retroviruses including HIV-1. TRIM5α 
molecules with Mamu 1, 3, 4, 5 and 8 B30.2 domains were found to restrict infection by 
HIV-1, FIV and EIAV, while the TRIM5α with Mamu 4 and 5 B30.2 domains were 
found to be unable to recognize HIV-2 additionally, none of the identified alleles was 
reported to have antiviral properties against SIV. Thus an observation that functional 
TRIM5α alleles exhibit differences in antiretroviral specificities. 
 
 
Mamu-1 VDVTLATNNISHAVIAEDKRQVSSRNPQIMYQAPGTLFTFPSLTNFNYCTGVLGSQSITS 60 
Mamu-8 VDVTLAPNNISHAVIAEDKRQVSSRNPQIMYQAPGTLFTFPSLTNFNYCTGVLGSQSITS 60 
Mamu-3 VDVTLAPNNISHAVIAEDKRQVSSRNPQIMYQAPGTLFTFPSLTNFNYCTGVLGSQSITS 60 
Mamu-5 VDVTLAPNNISHAVIAEDKRQVSSRNTQIMYQSPGTLF--QSLTNFNYCTGVLGSQSITS 58 
Mamu-4 VDVTLAPNNISHAVIAEDKRQVSSRNPQIMYQSPGTLF--QSLTNFNYCTGVLGSQSITS 58 
Mamu-7 VDVTLAPNNISHVVIAEDKRQVSSRNPQIMYRTQGTLF--QSLTNFIYCTGVLGSQSITS 58 
         ******.*****.*************.****:: **** : ***** ************* 
  
  
 
Mamu-1 GKHYWEVDVSKKSAWILGVCAGFQSDAMYNIEQNENYQPKYGYWVIGLQEGVKYSVFQDG 120 
Mamu-8 GKHYWEVDVSKKSAWILGVCAGFQSDAMYNIEQNENYQPKYDYWVIGLQEGVKYSVFQDG 120 
Mamu-3 GKHYWEVDVSKKSAWILGVCAGFQSDAMYNIEQNENYQPKYGYWVIGLQEGVKYSVFQDG 120 
Mamu-5 GKHYWEVDVSKKSAWILGVCAGFQSDAMYNIEQNENYQPKYGYWVIGLQEGVKYSVFQDG 118 
Mamu-4 GKHYWEVDVSKKSAWILGVCAGFQSDAMYNIEQNENYQPKYGYWVIGLQEGVKYSVFQDG 118 
Mamu-7 GKHYWEVDVSKKSAWILGVCAGFQPDAMYNIEQNENYQPKYGYWVIGLQEGVKYSVFQDG 118 
         ************************.****************.****************** 
   
 
Mamu-1 SSHTPFAPFIVPLSVIICPDRVGVFVDYEACTVSFFNITNHGFLIYKFSQCSFSKPVFPY 180 
Mamu-8 SSHTPFAPFIVPLSVIICPDRVGVFVDYEACTVSFFNITNHGFLIYKFSQCSFSKPVFPY 180 
Mamu-3 SSHTPFAPFIVPLSVIICPDRVGVFVDYEACTVSFFNITNHGFLIYKFSQCSFSKPVFPY 180 
Mamu-5 SLHTPFAPFIVPLSVIICPDRVGVFVDYEACTVSFFNITNHGFLIYKFSQCSFSKPVFPY 178 
Mamu-4 SLHTPFAPFIVPLSVIICPDRVGVFVDYEACTVSFFNITNHGFLIYKFSQCSFSKPVFPY 178 
Mamu-7 SSHTPFAPFIVPLSDYLS------------------------------------------ 136 
         * ************ 
              V3 
 
A Invariant 
A Synonymous 
A Nonsynonymous 
 
Fig 2: Sequences of the rhesus macaques B30.2 domanins used in this study. The 
rhesus macaques amino acid sequences of the Mamu alleles used in this study. 
Mutations and deletions are shown in red, asterisks indicate conserved regions and gaps 
indicate deletions. (reproduced with permission from S. Wilson) 
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This project revisits the experimental work by S. Wilson; therefore this work is set to 
test the restriction properties of the identified various B30.2 domains, and a synthetic 
truncated Mamu1 (FDFS), against a range of retroviruses. Furthermore, the work will 
also test the dominant negative properties of the identified Mamu alleles against HIV-1 
and HIV-2.  In conclusion, this project sets out to improve the SIV/rhesus macaques 
animal model for AIDS. This will be undertaken by closely examining whether 
polymorphism within the B30.2 antiviral determinant of TRIM5 is indeed partially 
responsible for the differences seen in disease progression following retroviral 
challenge. Therefore this work seeks to establish if particular alleles are in fact 
associated with better or worse disease progression in rhesus macaques challenged with 
SIVmac and a range of its derivatives.    
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Aims and objectives 
The aim of this work is to improve the SIV/rhesus macaques animal model for AIDS by 
examining the contribution of TRIM5α polymorphism to disease progression. We 
retrospectively sequenced the B30.2 domain, which encodes the antiviral specificity 
determinant of TRIM5α, from at least 60 Indian and Chinese Rhesus macaques enrolled 
in vaccine studies. This was done to establish if particular alleles are associated with 
better or worse disease progression following retroviral infection. An in vitro 
assessment of the ability of the identified alleles to restrict infection by a range of 
retroviruses was undertaken using established techniques; additionally this project also 
assessed the dominant negative properties of the identified TRIM5α alleles against HIV-
1 and HIV-2. The overall objective of this work was to associate differences in 
susceptibility to retroviral infections with particular TRIM5α sequences, focusing on the 
B30.2 domain antiviral determinant. 
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Materials and methods  
Cell lines 
A highly permissive feline cell line, CRFK cell line was propagated in Dulbecco’s 
Modified Eagle Medium (DMEM), supplied by GIBCO supplemented with 10% Fetal 
Calf Serum (FCS) and 1% penicillin and streptomycin at 37°C, 5% CO2. Once 
confluent, the cells were passaged at a dilution factor of 1:4. Human kidney cell line, 
HEK 293T cells were also grown in DMEM with 15% FCS and 1% penicillin and 
streptomycin and incubated at 37°C, 10% CO2. FRHK4 cells, expressing HA-tagged 
TRIM5α rhesus macaques cells (a generous gift from S. Wilson) were treated as above 
for CRFK cells. FRHK4 cells are rhesus macaques cells that endogenously express 
TRIM5α. 
 
Bacterial Transformation 
Plasmids listed in Table 3 (generous gifts from S. Wilson and T. Schaller) were 
introduced into Escherichia coli (E. coli) cells strain HB101 using heat shock of 
chemically competent E.coli cells (a generous gift from L. Ylinen) and plated on 
Ampicillin-containing agar plates that were incubated overnight at 37oC. A single 
colony of the transformed E.coli was picked and used to inoculate a flask containing 
500ml Luria-Bertani liquid broth medium and 1% Ampicillin. The recombinant plasmid 
was purified using the Qiagen® Midiprep method in accordance with the 
manufacturer’s instructions and the yield was determined using nanodrop 
spectrophotometry. 
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Table 3: Plasmids and expression vectors used in this study all plasmids were 
generated as previously described (30, 35-43). 
 
 
1. pSIV GFP 
2. pSIV 3+ (SIVmac gag-pol expresser) 
3. pCIG3N (MLV-N gag-pol expresser) 
4. pCIG3B (MLV-B gag-pol expresser) 
5. MLV-N GFP 
6. MLV-B GFP 
7. pONY3.1 (EIAV gag-pol expresser) 
8. pONY4.0Z (pEIAV GFP) 
9. pHR'SINcSGW (HIV-1 GFP) (a generous gift from A Thrasher) 
10. p8.91 (HIV-1 Gag-pol) (generous gift from D. Trono)  
11. pSVR∆NBPuro∆H (HIV-2 vector encoding GFP) 
12. pSVR∆NB (HIV-2 RODA gag-pol expression vector)  
13. VSV-G expression vector, pMDG (generous gift from D. Trono) 
14. MLV viral vector called pEXN (which contains a G418 selectable marker, 
and is under the control of the cytomegalovirus (CMV) IE promoter) 
(generous gift from P. Bieniasz) 
 
 
 
 
 
Transient transfection (generating pseudotyped retroviral vectors) 
VSV-G psedotyped GFP expressing retroviral vectors were generated by transfecting a 
10-cm plate of HEK 293T cells with three plasmids (Fig 3A) namely 1µg gag-pol, 1.5µg 
vector genome/GFP and 1µg VSV-G expression vectors using Fugene-6 (Roche). The 
introduction of the three plasmids into HEK 293T cells resulted in the formation of 
virions (Fig 3B) that are released into the supernatant and collected at 48 and 72 hours 
after transfection, filtered, stored at -80oC and subsequently used to infect the CRFK 
cell line. 1X105 cells per well (plated in a six-well plate) were infected with 3-fold 
serially diluted virus. Infected cells were incubated for 48 hours and infectivity was 
determined by measuring GFP expressing cells using a fluorescence-activated cell sorter 
(FACS) and the percentage infected cells was plotted against the input dose of each 
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virus, measured in microlitres per millilitre. The titre was determined by calculating the 
number of infected cells per 1ml of virus supernatant. It is assumed that 2X105 cells are 
present in a plate on the day of transfection.  
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Fig 3: Expression vectors used to express viral genes, transfection and an 
infectivity assay. Expression vectors used in transient transfection of 293T cells (A). 
Plasmids encoding gal-pol expression vectors and GFP are pseudotyped with a VSV-G 
envelope from vesicular stomatisis virus, (the VSV-G envelope glycoprotein allows 
efficient entry into a wide range of vertebrate cells) and transfected into 293T cells. The 
supernatant containing virions is collected after 48 and 72 hours, filtered and used to 
infect CRFK cells and infectivity is assayed by FACS (B). N.B all retroviral coding 
sequence has been removed. (reproduced with permission from Greg Towers) 
 
 
TRIM5 expression in CRFK  
HA-tagged TRIM5α molecules were expressed in CRFK cells using the MLV viral 
vector, pEXN (which contains a G418 selectable marker). An empty vector was also 
introduced into CRFK cells and this functioned as a negative control. HA-tagged 
TRIM5α expressing cells and those containing empty vectors (a generous gift from S. 
Wilson) were kept frozen in liquid nitrogen and resuscitated by placing in a water bath 
at 37oC. Once thawed the cells were re-suspended in fresh DMEM medium and 
incubated for 48 hours to encourage propagation. Confluent cells were plated on six 
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well plates at 1X105 cells per well, incubated overnight and challenged with 3-fold 
serial dilutions of GFP expressing viruses in the presence of polybrene which enhances 
cell infection.  
 
 
 
FACS analysis  
After 48 hours, cells were washed in phosphate-buffer saline (PBS), trypsinised and 
transferred into FACS tubes, fixed with 2% formaldehyde and cell infection was 
measured using FACS. Infectious titres were calculated and used to plot bar charts. 
These values were generated using 3 different virus doses and error bars are the 
standard deviation of the mean of these titres. Thus we were able to compare viral titres 
following the expression of TRIM5α. 
 
 
 
 
Dominant negative assays 
 
Frozen FRHK4 were thawed and propagated as above for CRFK cells. Confluent cells 
were plated on six well plates at 1X105 cells per well, incubated overnight, different 
doses of TRIM34 and all TRIM5α alleles used in this study with the exception of FDFS 
(in viral expression vectors) were added to each plate, mixed by shaking for 5 minutes 
and spinoculated in a centrifuge at 500rpm for 2 hours to sediment the virus, cells were 
then incubated at overnight 37°C, 5% CO2 to allow for infection. Cells were then 
distributed in duplicate and one plate of each of the expressed TRIM5 alleles and 
TRIM34 was challenged with serial dilutions of GFP expressing HIV-1 or HIV-2 
viruses in the presence of polybrene. Cells in parallel plates were lysed to extract 
Charlotte Maplanka 
Project Report 
 24 
protein which was transferred into 1.5ml tubes and its expression assessed by western 
blot. 
 
 
Western blot 
 
Cells were re-suspended in loading buffer (see appendix), sonicated for 10 seconds and 
centrifuged at 1200rpm for 10 minutes. The supernatant was transferred into clean tubes 
and protein denatured by boiling for 5 minutes. 15µl of each sample was loaded onto a 
12.5% SDS-PAGE gel (see appendix) and separated by running the gel at 150 volts for 
60 minutes. Protein was then transferred to Hybond-P (GE Healthcare UK limited) 
(activated by immersing in methanol and transfer buffer for a few seconds) using a 
semi-dry transfer method. Transfer was performed at according to manufacturer’s 
instructions.  
To prevent non-specific binding, membranes were incubated in 10ml of blocking 
solution (TBS-T + 5% dried milk powder) for one hour at room temperature. 
Membranes were then probed with an anti HA tag Ab, HA.11 Monoclonal Antibody 
(Covance, UK [Cat nb MMS-101P]) directed at the HA tag at a concentration of 1:4000 
in 1% milk TBS-T, for 3 hours at room temperature. The membranes were extensively 
washed with TBS-T buffer to remove unbound molecules, a secondary antibody, anti-
mouse IgG horseradish peroxidase linked whole antibody (from sheep) (GE Healthcare, 
UK [cat nb NA931V]) was used to bind the primary antibody for 1 hour at room 
temperature and then washed as before. The ECL Plus Western Blot detection system 
was used in accordance with the manufacturer’s instructions. Gels were exposed to X-
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ray films, amersham hyperfilm (ECL, GE Healthcare UK limited) for 5 minutes to 
detect bands. 
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Results 
TRIM5α was first described in 2004 and has been previously shown to possess antiviral 
activity against retroviruses in a species-specific manner. For example human TRIM5α 
cannot restrict HIV-1. Conversely, rhesus macaques TRIM5α potently restricts HIV-1 
(3, 4). We asked if there might also be specificity variation within a species as this 
might have an important effect on vaccine trials using rhesus macaques enrolled as 
AIDS animal models. The B30.2 domain of TRIM5α is known to encode the antiviral 
specificity and the discovery by Newman et al. that polymorphism exists within this 
domain highlighted the possibility of intra-species specific retroviral restriction. Once 
different alleles of the B30.2 domain, namely the Macaca mulatta (Mamu) alleles were 
sequenced and identified we aimed to test their restriction properties against a range of 
retroviruses. Initially the identified Mamu alleles were appended to the remainder of the 
TRIM5 molecule, HA-tagged and successfully expressed in a highly permissive feline 
cell line, CRFK. 
 
Transient Transfections (generating pseudotyped retroviral vectors) 
A range of VSV-G pseudotyped retroviral vectors expressing GFP as a reporter protein 
were generated by the transient transfection of HEK 293T cells. Once these were 
harvested their infectious titres were assessed by infecting CRFK cells with each virus. 
Infected cells were incubated for 48 hours at 37°C 5% CO2. The percentage of infection 
was determined by FACS analysis which counts GFP positive cells from which the viral 
titres were calculated and viral infectious titres were determined by calculating the 
number of infected cells per µl extrapolated to 1ml (Fig 4 and Table 4). Initial stocks of 
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SIVmac and FIV were found to have titres that were lower than expected therefore 
another batch was made using a fresh culture of HEK 293T cells and a significant 
improvement on titres of both viral stocks was achieved but more so for SIVmac which 
showed at least a 10-fold increase.  
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Fig 4: Log plots showing infectious titres (determined by calculating the number of 
infected cells per µl extrapolated to 1ml) of retroviruses used in this study. 
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Table 4: Titres of GFP expressing retroviruses used this study 
 
Virus Name Titre infectious units per 
millilitre (iu/ml) 
HIV-1  1.1 X 107 
SIVmac (initial stock) 1.11 X 105 
FIV (initial stock) 1.55 X 105 
HIV-2 2.98 X 106 
MLV-B 1.81 X 106 
MLV-N  2.71 X 106 
FIV  1.19 X 106 
SIVmac  2.16 X 106 
EIAV 1.51 X 105 
 
 
Restriction properties of various B30.2 alleles of TRIM5α  
We investigated whether polymorphism within the B30.2 domain of TRIM5αrh led to 
differential restriction of a range of retroviruses. G418 selected ‘bulk’ populations of 
CRFK cells expressing Mamu alleles, Mamu 1, 3, 4, 5, 7, 8 or FDFS appended to the 
RBCC domains of Mamu1 were infected with serial dilutions of the GFP expressing 
viruses (Figs 5) and incubated for 48 hours at 37°C. CRFKs transduced with an empty 
vector (EXN) and untransduced CRFKs both served as negative controls. The empty 
vector illustrated the effects of expressing the vector alone on viral restriction while the 
untransduced cells served as a baseline for the infectivity of each virus. The percentage 
of infected cells was assessed by FACS and plotted in infectious units per millilitre as 
before. Bar charts were generated using 3 different virus doses. The error bars are the 
standard deviation from the mean of these titres and these allowed the comparison of 
viral titres following the expression of TRIM5α encoding Mamu 1, 3, 4, 5, 7, 8 and 
FDFS B30.2 domains in CRFK cells and the EXN expressing and untransduced CRFKs 
(Fig 5).  
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I: EIAV
H: HIV-2G: HIV-1
F: MLV-NE: MLV-B
D: SIVmacC: SIVmac (initial stock)
B: FIVA: FIV (Initial stock)
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Fig 5: Effects of polymorphism within TRIM5αrh B30.2 domains on retroviral 
infection.  CRFK cells expressing TRIM5α molecules encoding various Mamu alleles 
and control CRFK cells transduced with an empty vector, EXN or untransduced were 
incubated with the indicated recombinant GFP expressing retroviruses. Bar charts show 
the infectious titres of each virus determined by counting the number of GFP positive 
cells. 
 
 
FIV infection was moderately restricted by Mamu 1, 3, 8, 4 and 5 alleles. Mamu 1 and 
3 alleles were more potent at suppressing this virus by up to 8-fold in comparison to the 
other alleles (up to 4-fold) while Mamu 7 and FDFS did not protect cells from infection 
with this virus (Fig 5A and B). This same trend was observed using either of the 
independently prepared viral stocks (Table 4). 
 
SIVmac infection was not restricted by any of our panel of rhesus TRIMs. None of the 
identified Mamu alleles were found to inhibit SIV infection (Figs 5C and D) and this 
finding is consisted with previous experiments (S. Wilson, unpublished results). 
Interestingly, cells expressing our TRIMs appear to be more permissive to SIVmac 
infection when compared with the untransduced cells, and those transduced with EXN 
(Figs 5C and D). This same trend was observed using either of the independently 
prepared viral stocks (Table 4). This suggests that expression of TRIM proteins might in 
fact increase cell susceptibility to this virus, perhaps due to dominant negative activity 
against undefined weak antivirals. It is also possible that TRIM5αrh expression in CRFK 
cells has deleterious effects that result in decreased cell proliferation. The reduced 
number of cells at the time of infection might increase the percentage infection resulting 
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in an apparent increase in susceptibility. This effect could be further examined using 
cell proliferation assays. 
 
MLV-B infection was not restricted by any of the Mamu alleles in this study (Fig 5E). 
This is consistent with published observations (16). 
 
MLV-N infection was not inhibited by the Mamu alleles in this study (Fig 5F). This is 
inconsistent with previous findings reporting that MLV-N is partially blocked by 
TRIM5αrh (44). Additionally, our findings also contradict the observations by Newman 
et al. who reported that Mamu 1, 3, 4 and 5 efficiently restrict MLV-N (3). In this study 
none of the Mamu alleles exhibited strong restriction against this virus and this is also 
consistent with unpublished results from our lab (S. Wilson, personal communication). 
It is possible that the creation of our hybrid TRIM5α molecules has resulted in the loss 
of restriction activity against this virus. However, in light of the fact that Mamu1, whose 
sequence is unaltered, does not restrict MLV-N infection in this assay, it is more likely 
that the expression levels of our TRIMs were too low to restrict MLV-N. The effects of 
reduced expression on MLV-N restriction were previously observed by Newman et al. 
(3) 
 
HIV-1 infection was restricted by Mamu 1, 3, 4, 5 and 8, by up to 10-fold. Additionally, 
FDFS showed a slight decrease in viral titres in comparison to the control cells (Fig 
5G). Protection of cells from infection with this virus specifically by Mamu 1, 3, 4, and 
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5 is consistent with previous findings by Newman et al. (3) Mamu7 a truncated allele, 
did not inhibit HIV-1(Fig 5G). 
 
HIV-2 infection was potently inhibited by Mamu1 and also inhibited by Mamu3 and 8 
by up to 8-fold. A slight decrease in infection was also seen in cells transduced with 
FDFS (~ 3-fold). Mamu 4, 5 and 7 did not exhibit any antiviral activity against this 
virus (Fig 5H). 
 
EIAV infection was restricted by all Mamu alleles tested in this study with the 
exception of Mamu7 and FDFS (Fig 5I).  
 
 
In summary, infection with FIV, HIV-1, HIV-2 and EIAV could be restricted by some 
of the Mamu alleles tested while cells where not protected from SIV, MLV-B and 
MLV-N in this study. This illustrates differential restriction by particular alleles. 
Mamu7, a truncated allele with a 44 amino acid deletion did not restrict any of our panel 
of retroviruses. This suggests that the truncation is large enough to disrupt the internal 
structure of the B30.2 domain; possibly resulting in a molecule that does not fold into a 
functional B30.2 domain. Additionally, the loss of amino acids on the V3 region (for 
substrate binding) which are conserved in other alleles suggests a loss of retroviral 
capsid binding properties. In brief, this highlights that the truncation found in the B30.2 
of this particular allele has possibly resulted in the loss of some essential residues that 
are necessary for viral recognition and binding. It is hard to imagine that this allele can 
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restrict any viruses however, its conservation within this species implies that it may 
have some protective properties against viruses that affect this species that have not yet 
been characterised. Interestingly, Mamu 4 and 5 are functional alleles, yet they do not 
restrict HIV-2. This suggests that the deletions and substitutions found in these alleles 
alter some determinants essential for HIV-2 restriction. Finally, these observations 
demonstrate that intra-species variation in the B30.2 domain results in different 
antiretroviral specificities. The maintenance of so many alleles within a population 
suggests balancing selection of the TRIM5α locus. This in turn suggests repeated 
exposure to divergent pathogenic retroviruses throughout recent macaques evolution. 
  
 
Dominant negative analysis 
The simultaneous expression of TRIM5γ and TRIM5δ with the wild type molecule 
illustrates that these two isoforms exert a dominant negative effect that represses 
restriction by TRIM5α. Their expression increases permissivity of cells to viral 
infection and rescues restricted infectivity (1, 2, 11). TRIM5α encoding a B-box 2 
mutation has also been found to exert a dominant negative effect on the antiretroviral 
activity of the wildtype TRIM5α against (5). Additionally, a functionally defective 
TRIM5α mutant with the RING and B-box deleted can hetrotrimerise with the wild type 
molecule and exert a dominant negative activity on retrovirus restriction (10). In this 
regard, we asked if the newly identified Mamu 7 with a truncated B30.2 also exhibits 
similar properties when co-expressed with an active allele and challenged with HIV-1 
and HIV-2. In addition, we asked if Mamu 4 and 5, found to lack antiviral properties 
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against HIV-2 have dominant negative effects on the active TRIM5α. We assessed 
dominant negative properties by co-expression of the wildtype TRIM5α with TRIM5α 
molecules encoding Mamu 1, 3, 8, 4, 5 and 7 and with TRIM34 as a positive control 
and an empty vector, EXN and untransduced cells as negative controls. TRIM34 
contains a RING, B-box, coiled-coil and carboxyl-terminal B30.2 domain and it is 
56.9% identical to TRIM5αrh yet it lacks antiretroviral activity and does not restrict 
HIV-1 (44, 45). Expression of this protein in cells results in increased susceptibility to 
HIV-1 infection when compared to cells transduced with an empty vector (44). This 
TRIM molecule was therefore used as a positive control in this experiment because it 
potently disrupts TRIM5 mediated restriction (44, 45). FRHK4 cells transduced with 
EXN and untransduced cells served as a negative control. The EXN control was 
important here because it shows that any apparent dominant negative effect is not 
caused by the Moloney MLV core used to deliver the EXN vector saturating the 
restriction factor.  
 
Western blot results to assess the expression of the TRIM5α molecules with various 
Mamu alleles and TRIM34 revealed faint bands at molecular mass marker around 
55kDa were visualised on the X-ray film, (results not shown) this is consistent with the 
size of the wild type monomer TRIM5αrh which has a molecular mass of 54 to 56 kDa. 
Unfortunately, the bands were too faint to scan and this experiment will be repeated. 
FRHK4 cells (homozygous for Mamu 1 TRIM5α) were transduced with TRIM5α 
molecules expressing various TRIM5α alleles or TRIM34 or an empty vector, and 
incubated for 48 hours as previously described. The cells were then infected with 
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serially diluted doses of GFP encoding HIV-1 and HIV-2. The percentage infection for 
each dose of GFP encoding virus was determined using FACS, and bar chart plots to 
analyse the data were constructed as previously described (Fig 6). 
 
Fig 6: Dominant negative properties of the identified Mamu alleles. The dominant 
negative effects of Mamu alleles against the wildtype TRIM5α was tested following co-
expression of the wildtype TRIM5α and various Mamu alleles and TRIM34 in FRHK4 
cells and incubation with HIV-1 and HIV-2. EXN denotes co-expression of the wildtype 
with an untransduced empty vector. 
 
 
 
 As expected, both HIV-1 and HIV-2 were restricted by the unmodified FHRK4 cells 
and those transduced with an empty vector. Furthermore, both viruses were restricted by 
FRHK4 exogenously expressing Mamu 1, 3 and 8 illustrating that these alleles have no 
dominant negative activity towards Mamu 1. Co-expression of Mamu 1 and Mamu 8 
showed additive restriction resulting in enhanced antiviral activity towards HIV-1 in 
comparison with unmodified FRHK cells. Conversely, the truncated Mamu7 was found 
to exert dominant negative activity against Mamu 1 weakly rescuing infectivity of both 
viruses particularly for HIV-1. This suggests that this allele can hetrotrimerise with the 
Mamu 1 and interfere with its ability to restrict HIV-1 and HIV-2. Mamu 4 and 5 
expression does not appear to rescue infectivity of either virus (infectivity is only 
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slightly attenuated in HIV-2) the FRHK4 cells expressing these proteins appear to 
restrict as well as unmodified cells. This is surprising in HIV-2 infection considering 
that neither allele restricts HIV-2 (Fig 5H).  
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Discussion 
Variations among primate TRIM5α sequences are responsible for differences in 
restriction properties towards retroviruses (5). The B30.2 domain encodes the main 
antiviral restriction determinant for TRIM5α (3). We analysed the restriction properties 
of TRIM5α molecules from individuals from the same species. We have confirmed that 
intra-species polymorphism of this molecule exists and have shown that it has an impact 
on retroviral restriction specificity. The retroviral capsid encodes the determinant for 
restriction susceptibility by a particular TRIM5α (10). This implies that the TRIM5α 
recognition and binding sites on retroviral capsid proteins are not exclusively conserved 
and thus there may be slight differences in viral susceptibility to the antiviral activity of 
a particular TRIM. Therefore this is taken to explain lack of inhibition of SIVmac, 
MLV-B and MLV-N by all of the identified and tested Mamu alleles. Although highly 
unlikely, it is also possible that the creation of our hybrid TRIM5α molecules has 
resulted in the loss of restriction properties against these viruses; alternatively, it is 
possible that the expression levels of our TRIMs were too low to restrict some of these 
viruses. Mamu7, the truncated allele moderately restricted HIV-2 although its restriction 
properties were less potent in comparison to the wildtype allele. Furthermore this allele 
did not inhibit the rest of the viruses in this study suggesting that the loss of 44 amino 
acids within the B30.2 of this allele has resulted in improper folding of the molecule and 
inability to confer viral recognition and binding properties. Interestingly, expression of 
Mamu7 together with the wildtype TRIM5α allele was found to slightly attenuate 
restriction in a dominant negative manner following challenge with HIV-1 and HIV-2. 
This suggests that this allele can trimerise with the wildtype allele and has not lost this 
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ability. TRIM34 was found to exert strong dominant negative properties towards the 
wildtype TRIM5α molecule following co-expression and challenge with HIV-1 and 
HIV-2. 
 
Polymorphism of TRIM5α is observed in this study and it is thought that the reason 
why these differences occur and are conserved in nature is because there are numerous 
retroviruses that have infected the rhesus macaques population and caused TRIM5α 
selection. Mamu 3 is the most common allele in both Indian and Chinese macaques 
(Table 2) and it is the most functional, with an effect on a par with Mamu 1. The 
frequency of this allele in this population highlights that balancing selection may have 
favoured it above other alleles for this reason. The conservation of a non-functional 
Mamu7 allele at high frequencies within the Indian macaques might be driven by 
toxicity of active TRIM5 molecules. Alternatively this allele might also protect animals 
from viruses that remain to be defined and are not tested in this study.  
 
In conclusion, we have shown that intra-species polymorphism within the TRIM5α 
molecule has an effect on retroviral restriction. Apart from Mamu 7, the truncated allele, 
none of the tested alleles were shown to exert a dominant negative effect towards Mamu 
1 following co-expression and retroviral challenge. These findings contribute to the 
understanding of cellular restriction factors which equally contribute to the 
improvement of animal model for AIDS as it will allow for the screening and selection 
of animals and also the exclusion of animals carrying alleles such as Mamu3 that might 
inhibit a virus of choice for an animal model. 
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Future work 
We have shown that intra-species polymorphism of the TRIM5α molecule has an effect 
on retroviral restriction. The next possible study would be to investigate the specific 
mutation that results in differences in restriction properties by examining the 
contribution of each point mutation or deletion that differs within the Mamu alleles. For 
example there are only three differences between the sequences of Mamu 3 and Mamu 4 
yet Mamu 4 does not restrict HIV-2 while Mamu 3 does. There is a need to elucidate if 
one of these differences is responsible for differential restriction properties against HIV-
2. A generation of B30.2 domains containing each of these differences on their own 
might highlight the mutation that is responsible for loss of HIV-2 restriction. It will also 
be interesting to consider why an apparently inactive allele of TRIM5 (Mamu 7) is 
retained within the macaque population at such high frequency.  
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Appendix  
 
Western Blot  
 
SDS-PAGE (12.5% Running Gel made to a total volume 30mls) 
 
30% acrylamide 
2% isoacrylamide 
20% SDS 
1M Tris-HCL (pH 8.8) 
1M Tris-HCL (pH 6.8) 
20% APS (ammonium persulfate) 
TEMED 
Deionised water 
 
 
Loading Buffer 
20% glycerol 
5.2% SDS 
200mM (pH 6.8) Tris-HCL 
Bromophenol Blue (BPB) 
Water 
300mM SDS (add on day of use) 
